Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05411315
Other study ID # STUDY02001496
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 17, 2022
Est. completion date July 14, 2023

Study information

Verified date February 2024
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators will conduct a pragmatic randomized trial to investigate the non-inferiority of restricted use of invasive arterial lines compared to standard arterial line use.


Description:

Patients in the medical intensive care unit (MICU) often receive arterial lines as standard of care, however there are little data to support this practice. Investigators will randomly assign consecutive weeks to either current practice(control) or to a more conservative practice of not placing invasive arterial lines except for limited indication indications as defined below (intervention). Patients entering during an intervention week will be treated according to the intervention practice throughout their ICU stay. Likewise, patients entering during a control week will be treated according to current standard practice. Permuted block randomization will be used to assure equal numbers of intervention and control weeks. All outcome measures will be obtained through EPIC data analytics and post-hospitalization phone calls. Weekly randomization codes will be generated by the study statisticians and delivered to MICU staff via sealed envelopes to be opened at the beginning of each week.


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date July 14, 2023
Est. primary completion date July 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All subjects admitted to the medical intensive care unit Exclusion Criterion: - All subjects <18 years of age.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Restricted-use of arterial catheter
The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
Standard-use of arterial catheter
The investigator will allow standard-use of arterial catheters

Locations

Country Name City State
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of days hospitalized in the medical intensive care unit (length-of-stay) Number of days hospitalized in the medical intensive care unit inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of days hospitalized in a non- medical intensive care unit (Hospital length-of-stay) Number of days hospitalized in a non- medical intensive care unit inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of days using a mechanical ventilator (Ventilator-days) Number of days spent on a mechanical ventilator inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of days using vasopressor medicines (vasopressor-days) Number of days using vasopressor medicines inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of blood transfusions received during hospitalization (packed red blood cell transfusions) Number of blood transfusions received during hospitalization inpatient hospitalization (approximately 1 to 30 days) and receiving approximately 0 - 10 blood transfusions
Secondary Number of participants experiencing a bloodstream infection related to invasive arterial catheter use Number of participants experiencing a bloodstream infection related to invasive arterial catheter use inpatient hospitalization (approximately 1 to 30 days) and experiencing 0 to 1 bloodstream infections
Secondary Number of participants experiencing a vascular injury related to the invasive arterial catheter vascular injuries include hematoma formation, ischemic limb, false aneurysm, limb injury inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of days subjects experiencing death within 28 days of medical intensive care unit while having received vasopressor medicines (28-day mortality while on vasopressors) Number of days subjects experiencing death within 28 days of medical intensive care unit while having received vasopressor medicines Inpatient or outpatient death within 1 to 28 days
Secondary Number of days subjects experiencing death within 28 days of medical intensive care unit from any cause (28-day all-cause mortality) Number of days subjects experiencing death within 28 days of medical intensive care unit from any cause Inpatient or outpatient death within 1 to 28 days
Secondary Number of days subjects experiencing death within 90 days of medical intensive care unit from any cause (90-day all-cause mortality) The outcome of death that has occurred for subjects from all causes after 90 days Inpatient or outpatient death within 1 to 90 days
Secondary Number of patients experiencing renal failure while hospitalized Renal failure is defined as any renal replacement therapy inpatient hospitalization (approximately 1 to 30 days)
Secondary Number of vasopressors used The quantity of vasopressors Inpatient hospitalization (approximately 1 to 60 days)
Secondary Number of ABG measurements The total quantity of ABG labs sent Inpatient hospitalization (approximately 1 to 60 days)
See also
  Status Clinical Trial Phase
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Active, not recruiting NCT02016599 - Effects of Transitional Circulation in ELBW Infants
Recruiting NCT05836610 - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates Phase 4
Completed NCT02907931 - Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status N/A
Completed NCT03215797 - Phenylephrine or Norepinephrine for a Better Hemodynamic Stability Phase 3
Suspended NCT02315937 - Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography' N/A
Recruiting NCT02532270 - Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring N/A
Completed NCT02802683 - Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery Phase 4
Completed NCT02437799 - Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia N/A
Completed NCT01930227 - Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients N/A
Completed NCT02146898 - The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery N/A
Not yet recruiting NCT01941472 - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness N/A
Recruiting NCT01434251 - Treatment of Hypotension of Prematurity (TOHOP) N/A
Withdrawn NCT01183741 - Accuracy of Non-Invasive Blood Pressure Measurement in Adults Phase 3
Completed NCT01592669 - Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia N/A
Completed NCT00991627 - Different Approaches to Maternal Hypotension During Cesarean Section Phase 4
Withdrawn NCT00750516 - Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet
Completed NCT00115726 - Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure Phase 4
Recruiting NCT05513066 - Management Arterial Hypotension During Planned Caesarean Section, Intravenous Ephedrine/Phenylephrine Mixture Versus Intravenous Baby Noradrenaline
Completed NCT04089644 - Manual vs Closed-loop Control of Mean Arterial Pressure N/A